Biochemistry
| Full details for "Infliximab/Inflectra Anti-Drug Antibodies". | |
|---|---|
Name |
Infliximab/Inflectra Anti-Drug Antibodies |
Alternative name/Profile |
IFX ADA or INF ADA Infliximab Anti-Drug Antibody Inflectra (Biosimilar Drug of Infliximab) Anti-Drug Antibody |
Department |
Biochemistry |
Investigation |
The presence of subtherapeutic drug levels in patients treated with IFX or INF may be caused by the development of anti-drug antibodies; that is, antibodies that target and lower the bioavailability of Infliximab or Inflectra. These antibodies neutralise activity of IFX and INF and are a major cause of loss of response |
Specimen type |
Serum |
Sample type |
|
Sample container & volume |
5 ml - Red Tube |
Frequency of analysis |
Twice monthly |
Turnaround time |
10 Working days |
Availability |
Currently St. James’s Hospital patients only |
Notes |
External users subject to service level agreement. Contact laboratory for further information Trough sample required taken immediately before next infusion Fasting not required Samples with gross haemolysis, lipaemia or icterus not suitable for assay Stability: Serum stable for up to 7 days at room temperature. For longer store at minimum -20oC |
Related links |
|
Reference range |
Negative antibodies: <10 AU/mL Positive antibodies: >10 AU/mL |
Last updated |
Fri, 16 Aug 2024 10:50:42 IST |